DCPH Stock Recent News

Deciphera Pharmaceuticals said on Monday Japan's ONO Pharmaceutical Co will acquire the company for $2.4 billion in cash.

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?

The consensus price target hints at a 48.5% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 59.6% in Deciphera Pharmaceuticals, Inc. (DCPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Deciphera (DCPH) reports better-than-expected fourth-quarter 2023 results, wherein both earnings and revenues beat their respective estimates, driven by increased Qinlock sales.

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024. In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 8:00 AM ET on Tuesday, Febr.

Deciphera Pharmaceuticals has seen a 50% upside with successful phase 3 trial results. DCPH has achieved positive data in a subpopulation of patients with KIT exon 11 primary mutation. The company's pivotal phase 3 study of vimseltinib in TGCT has met primary and secondary endpoints, with a high objective response rate.

Deciphera Pharmaceuticals continues to make progress with its flagship drug ripretinib, with positive phase 3 results and ongoing trials. They are also working on commercializing the CSF1R inhibitor vimseltinib, with promising response rates in phase 1/2 and phase 3 trials. Financially, DCPH has a strong cash position and increasing revenues, but high expenses and the need for profitability remain challenges.

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 4:30 PM PT / 7:30 PM ET. A live webcast of the event will be available on the “Events and Pres.

Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sales. The stock rises 17%.